SREBF1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, overexpression of SREBP-1c has been shown to increase de novo lipogenesis, hepatic lipid accumulation, and insulin resistance, which could affect the pathogenesis of MASLD [55].